Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT04243447
Active, not recruiting Observational

Identification of Predictors for Clinical Outcomes in Femoroacetabular Impingement Surgery

NCT04243447 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2020-02-02
Last updated
2025-10-03

Condition(s) studied

Femoracetabular Impingement

Study summary

The overarching goal of the study is to improve the surgical treatment outcomes of FAI, which is affecting an increasing number of military personnel and young active individuals in the general population. The proposed study will investigate critical patient, disease, and surgical treatment predictors of FAI surgery outcomes.

Eligibility

Sex
ALL
Min age
14 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 14 - 40 years 2. Skeletally Mature 3. Failure of 6 weeks of conservative treatment 4. Primary surgery (Hip Arthroscopic Treatment) a. Surgical treatment of FAI with hip arthroscopy 5. Tonnis 0 -1 OA, with greater than 2 mm of joint space 6. Clinical diagnosis of FAI (cam or combined; alpha \>50 degrees) Exclusion Criteria: 1. Not a surgical candidate 2. Skeletally Immature 3. Acetabular Dysplasia (LCEA \< 20) 4. Tonnis 2+ OA 5. Previous ipsilateral hip surgery 6. Previous major hip trauma (hip fractures, hip dislocations) 7. Additional disease processes (e.g., Avascular Necrosis (AVN), synovial disease, Ehlers-Danlos Syndrome (EDS), neuromuscular disorders) 8. Unable to consent due to mental faculty 9. Pregnant women 10. Non-English speaking patients 11. Prisoners or other vulnerable populations

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
University of Colorado Aurora Colorado
University of Iowa Iowa City Iowa
Boston Children's Hospital Boston Massachusetts
University of Michigan Ann Arbor Michigan
Twin Cities Orthopedics Edina Minnesota
Mayo Clinic Rochester Minnesota
Washington University School of Medicine St Louis Missouri
Scottish Rite Hospital for Children Dallas Texas
San Antonio Military Medical Center San Antonio Texas
University of Wisconsin, Madison Madison Wisconsin
Children's Hospital of Eastern Ontario Ottawa Ontario
The Ottawa Hospital Ottawa Ontario
CHU de Quebec - Universite Laval Québec Quebec

More Washington University School of Medicine trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04243447 on ClinicalTrials.gov ↗ ← All trials in Canada